Cargando…
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2
Mutations in the ataxin-2 gene (ATXN2) cause the neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). A therapeutic strategy using antisense oligonucleotides targeting ATXN2 has entered clinical trial in humans. Additional ways to decrease ataxin-...
Autores principales: | Kim, Garam, Nakayama, Lisa, Blum, Jacob A., Akiyama, Tetsuya, Boeynaems, Steven, Chakraborty, Meenakshi, Couthouis, Julien, Tassoni-Tsuchida, Eduardo, Rodriguez, Caitlin M., Bassik, Michael C., Gitler, Aaron D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664452/ https://www.ncbi.nlm.nih.gov/pubmed/36288714 http://dx.doi.org/10.1016/j.celrep.2022.111508 |
Ejemplares similares
-
These violent repeats have violent extends
por: Couthouis, Julien, et al.
Publicado: (2018) -
Model Organisms Reveal Insight into Human Neurodegenerative Disease: Ataxin-2 Intermediate-Length Polyglutamine Expansions Are a Risk Factor for ALS
por: Bonini, Nancy M., et al.
Publicado: (2011) -
Targeted Exon Capture and Sequencing in Sporadic Amyotrophic Lateral Sclerosis
por: Couthouis, Julien, et al.
Publicado: (2014) -
CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9orf72 dipeptide repeat protein toxicity
por: Kramer, Nicholas J., et al.
Publicado: (2018) -
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
por: Elden, Andrew C., et al.
Publicado: (2010)